Investigational personalized vaccine provides clinical benefit for some patients with resected head and neck cancers
TG4050, a personalized neoantigen vaccine, induced tumor-specific immune responses and led to low rates of disease relapse in patients with surgically resected HPV-negative head and neck squamous cell cancer (HNSCC), according ...
Apr 9, 2024
0
14